AR064692A1 - Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos - Google Patents

Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos

Info

Publication number
AR064692A1
AR064692A1 ARP070105964A ARP070105964A AR064692A1 AR 064692 A1 AR064692 A1 AR 064692A1 AR P070105964 A ARP070105964 A AR P070105964A AR P070105964 A ARP070105964 A AR P070105964A AR 064692 A1 AR064692 A1 AR 064692A1
Authority
AR
Argentina
Prior art keywords
hydrogen
derivatives
oxindol
drugs
understand
Prior art date
Application number
ARP070105964A
Other languages
English (en)
Inventor
Liliane Unger
Wilfried Homberger
Thorsten Oost
Wolfgang Wernet
Herve Geneste
Astrid Netz
Wilfried Martin Braje
Wilfried Lubisch
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR064692A1 publication Critical patent/AR064692A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Derivados de oxindol de la formula general (1), medicamentos que los comprenden, y su uso para la profilaxis y/o el tratamiento de enfermedades relacionadas con el receptor de vasopresina V1b. Reivindicacion 1: Compuestos caracterizado porque comprende la formula general (1) en donde R1 es etoxi; R2 es hidrogeno; R3 es ciano; R4 es hidrogeno; R5 es hidrogeno, metoxi o etoxi; R6 es hidrogeno o metoxi; R7 es hidrogeno, metilo, etilo, n-propilo o isopropilo; X1 es -NH-; X2 es N o CH; X3 es N o CH; donde X2 y X3 no son simultáneamente N; y las sales aceptables para uso farmacéutico, formas tautoméricas y prodrogas de los mismos.
ARP070105964A 2006-12-30 2007-12-28 Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos AR064692A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006062506 2006-12-30
DE102006062507 2006-12-30
DE102006062508 2006-12-30
DE102006062505 2006-12-30

Publications (1)

Publication Number Publication Date
AR064692A1 true AR064692A1 (es) 2009-04-22

Family

ID=39125247

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP070105964A AR064692A1 (es) 2006-12-30 2007-12-28 Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
ARP100102572A AR077415A2 (es) 2006-12-30 2010-07-15 Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos
ARP100102571A AR077478A2 (es) 2006-12-30 2010-07-15 Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100102572A AR077415A2 (es) 2006-12-30 2010-07-15 Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos
ARP100102571A AR077478A2 (es) 2006-12-30 2010-07-15 Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos

Country Status (22)

Country Link
US (4) US8815868B2 (es)
EP (1) EP2114923B1 (es)
JP (1) JP5318781B2 (es)
KR (1) KR101485326B1 (es)
AR (3) AR064692A1 (es)
AU (1) AU2007341236B2 (es)
BR (1) BRPI0720866A2 (es)
CA (1) CA2673584C (es)
CR (1) CR10900A (es)
ES (1) ES2523320T3 (es)
GT (1) GT200900187A (es)
HK (1) HK1132740A1 (es)
IL (1) IL199265A (es)
MX (1) MX2009007104A (es)
NZ (1) NZ577720A (es)
PE (2) PE20121442A1 (es)
SA (1) SA07280709B1 (es)
TW (1) TWI423804B (es)
UA (1) UA96785C2 (es)
UY (1) UY30846A1 (es)
WO (1) WO2008080973A1 (es)
ZA (1) ZA200904363B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2009071691A2 (de) * 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Oxindol-derivate und ihre verwendung als medikament
MX2010006202A (es) * 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CN102026995B (zh) * 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
JP5595926B2 (ja) * 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
SG188781A1 (en) 2007-12-27 2013-04-30 Abbott Gmbh & Co Kg Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
CA2763931A1 (en) * 2009-06-10 2010-12-16 Abbott Gmbh & Co. Kg Use of substituted oxindole derivatives for the treatment and prophylaxis of pain
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
CA2903141A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
US9273036B2 (en) 2013-03-14 2016-03-01 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
US9862704B2 (en) 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2017076932A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
EP3371169B1 (en) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964896A (en) 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
CH623971B5 (de) 1976-06-04 1982-01-15 Hoechst Ag Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller.
WO1993013083A1 (en) 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5914328A (en) * 1992-10-09 1999-06-22 Abbott Laboratories Heterocyclic ether compounds useful in controlling neurotransmitter release
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
DK1047690T3 (da) 1997-12-19 2004-07-05 Abbott Lab Heterocykliske ether- og thioetherforbindelser, som er anvendelige til regulering af kemisk, synaptisk overförsel
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU4230799A (en) 1998-06-16 2000-01-05 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6207863B1 (en) * 1998-08-11 2001-03-27 Rohm And Haas Company Synthesis of haloformimine compounds
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
CN1192028C (zh) 1999-05-21 2005-03-09 艾博特公司 用作中枢神经系统药物的杂环取代的氨基氮杂环
US6833370B1 (en) * 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
CA2376061A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
US6579880B2 (en) 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
FR2810320B1 (fr) * 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
PT1379525E (pt) 2001-02-21 2007-12-04 Astrazeneca Ab Compostos heteropolicíclicos e sua utilização como antagonistas dos receptores metabotrópicos de glutamato
DE10148598A1 (de) 2001-04-19 2002-10-24 Bayer Ag Neue Arylsulfonamide als antivirale Mittel
CA2449544A1 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2005511613A (ja) 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
BR0313662A (pt) 2002-08-20 2005-06-14 Procter & Gamble Método para produção de composições detergentes em gel lìquido contendo solvente anidro para lavagem de pratos em lavadora automática
HUE031794T2 (en) 2003-04-11 2017-08-28 Ptc Therapeutics Inc 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
DE102004033834A1 (de) * 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006047392A2 (en) 2004-10-21 2006-05-04 The Trustees Of Columbia University In The City Of New York Nicotinic-opioid synergy for analgesia
US8378109B2 (en) 2004-12-07 2013-02-19 The Regents Of The University Of California Labeled ALPHA4BETA2 ligands and methods therefor
JP2008525524A (ja) 2004-12-28 2008-07-17 アストラゼネカ・アクチエボラーグ アリールスルホンアミドモジュレーター
EP1831197A2 (de) 2004-12-31 2007-09-12 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
US20080261999A1 (en) 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
MX2007011693A (es) 2005-03-24 2008-03-11 Abbott Gmbh & Co Kg Derivados de oxindoles sustituidos, farmacos que contienen dichos derivados y uso de los mismos.
DE102005014904A1 (de) * 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
RU2007139255A (ru) 2005-04-26 2009-06-10 Ньюросерч А/С (DK) Новые оксадиазольные производные и их медицинское применение
WO2007149395A2 (en) 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2008080970A1 (en) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
WO2008080972A1 (en) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor modulator
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008080971A1 (en) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
EP2297140A4 (en) 2008-06-06 2012-05-02 Abbott Lab NOVEL 1,2,4-OXADIAZOLE COMPOUNDS AND METHODS OF USE
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
CN101730041A (zh) 2009-06-26 2010-06-09 中兴通讯股份有限公司 一种基于用户当前所在时区的策略和计费控制方法及系统

Also Published As

Publication number Publication date
EP2114923A1 (en) 2009-11-11
US20150352110A1 (en) 2015-12-10
NZ577720A (en) 2012-02-24
AU2007341236B2 (en) 2013-03-21
PE20081557A1 (es) 2008-10-30
KR20090099001A (ko) 2009-09-18
AU2007341236A1 (en) 2008-07-10
US20140378471A1 (en) 2014-12-25
EP2114923B1 (en) 2014-08-06
UA96785C2 (uk) 2011-12-12
TW200848045A (en) 2008-12-16
CR10900A (es) 2010-01-11
JP2010514739A (ja) 2010-05-06
MX2009007104A (es) 2009-09-18
BRPI0720866A2 (pt) 2014-03-04
SA07280709B1 (ar) 2010-09-29
HK1132740A1 (en) 2010-03-05
AR077415A2 (es) 2011-08-24
US20120322809A1 (en) 2012-12-20
PE20121442A1 (es) 2012-10-26
KR101485326B1 (ko) 2015-01-22
TWI423804B (zh) 2014-01-21
WO2008080973A1 (en) 2008-07-10
US8859557B2 (en) 2014-10-14
JP5318781B2 (ja) 2013-10-16
ZA200904363B (en) 2012-09-26
CA2673584A1 (en) 2008-07-10
ES2523320T3 (es) 2014-11-24
IL199265A (en) 2015-06-30
US8815868B2 (en) 2014-08-26
US20110124658A1 (en) 2011-05-26
UY30846A1 (es) 2008-07-31
CA2673584C (en) 2015-10-27
GT200900187A (es) 2015-10-14
AR077478A2 (es) 2011-08-31

Similar Documents

Publication Publication Date Title
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
UY26782A1 (es) Derivados del benzotiazol
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
ECSP056019A (es) 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune
UY27918A1 (es) Derivados de benzodioxol
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
PA8544901A1 (es) Derivados de oxazol
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
ECSP077412A (es) Derivados de indol tetracíclicos como agentes antivíricos
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure